39073-07-9

Basic information

• Product Name: 2,7-DIBROMODIBENZO-PARA-DIOXIN
• Synonyms: 2,7-DIBROMODIBENZO-PARA-DIOXIN;2,7-DibroMo-dibenzo[1,4]dioxine;Dibenzo[b,e][1,4]dioxin, 2,7-dibromo-;2,7-Dibromodibenzo[b,e][1,4]dioxin
• CAS NO: 39073-07-9
• Molecular Formula: C₁₂H₆Br₂O₂
• Molecular Weight: 341.9828
• Mol File: 39073-07-9.mol

Chemical Properties

• Melting Point: 193 °C
• Boiling Point: 376.6°Cat760mmHg
• Flash Point: 154.5°C
• Appearance: /
• Density: 1.894g/cm³
• Vapor Pressure: 1.55E-05mmHg at 25°C
• Refractive Index: 1.674
• CAS DataBase Reference: 2,7-DIBROMODIBENZO-PARA-DIOXIN(CAS DataBase Reference)
• NIST Chemistry Reference: 2,7-DIBROMODIBENZO-PARA-DIOXIN(39073-07-9)
• EPA Substance Registry System: 2,7-DIBROMODIBENZO-PARA-DIOXIN(39073-07-9)

Safety Data

• Hazardous Substances Data: 39073-07-9(Hazardous Substances Data)

Usage

Uses

Given the highly toxic and harmful nature of 2,7-Dibromodibenzo-p-dioxin, it does not have any beneficial applications or uses in industries or other sectors. Its presence is generally considered a contaminant that needs to be avoided or mitigated due to the significant risks it poses to human health and the environment. Efforts are focused on reducing its formation, monitoring its presence, and managing its impact through regulatory measures and environmental cleanup initiatives.

InChI:InChI=1/C12H6Br2O2/c13-7-1-3-9-11(5-7)16-10-4-2-8(14)6-12(10)15-9/h1-6H

Upstream product

• 262-12-4 dioxin 
• 1354655-73-4 C₁₂H₇Br₂NO₄ 
• 1354655-72-3 C₁₃H₉Br₂NO₄ 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 37942-01-1 5-bromo-2-methoxyphenol 

Downstream Products

• 50585-41-6 2,3,7,8-tetrabromodibenzodioxin 

Relevant articles and documents

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity

HCV NS5A inhibitors have demonstrated impressive in vitro potency profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed dose combination regimen for the treatment of HCV infection. Herein, we describe research efforts that led to the discovery of a series of fused tricyclic core containing HCV NS5A inhibitors such as 24, 39, 40, 43, and 44 which have pan-genotype activity and are orally bioavailable in the rat.

FUSED TRICYCLIC COMPOUNDS AND USE THEREOF FOR TREATING VIRAL DISEASES

Fused tricyclic compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein X1, X2, X3, X4, Y1, Y2, M1, M2, Ra, Rb, R1, R2 and R6 are as defined in the description. Compositions comprising at least one fused tricyclic compound and methods of using the fused tricyclic compounds for treating or preventing HCV infection in a patient are also disclosed.

Syntheses of dibenzodioxin derivatives via iron complexes, and further functionalizations via directed metallation

Double nucleophilic aromatic substitution reactions between (cyclopentadienyl)(η6-1,2-dichlorobenzene)iron(1 +) salts and substituted 1,2-benzenediols have been carried out under mild conditions to prepare 6-dibenzodioxin>iron(1 +) complexes functionalized in the 1- or 2-position with an alkyl, aldehyde, carboxylic acid, methoxycarbonyl, carboxamide, or hydroxy group. 3-Methyl- and 4-methyl-(η6-1,2-dichlorobenzene)iron complexes were treated with substituted 1,2-benzenediols to effect functionalization of both aromatic rings of the heterocycle.The dibenzodioxin ligands were liberated routinely by irradiation with ultraviolet light.Directed deprotonation of the free functionalized dibenzodioxins with an alkyllithium reagent followed by quenching with a variety of electrophiles yielded further derivatives, including two new isoindolone systems.